A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

N/ANot Yet RecruitingNCT07544862

Chengdu Kangnuoxing Biopharma,Inc.1,000 enrolled

Overview

This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Atopic Dermatitis (AD)

Interventions

StapokibartBIOLOGICAL

subcutaneous injection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Trial participants aged 18 years or older at baseline, with no restrictions on gender. * Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study. Exclusion Criteria: * Known history of allergic reaction to Stapokibart Injection. * Trial participants currently or plan participating in any interventional clinical trial. * Trial participants with hematologic malignancies. * Women with pregnant. * Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.

Locations (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

The incidence rate of adverse reactions

Number of Adverse Reactions is calculated based on Adverse Events and Serious Adverse Events that were assessed by the investigator as related to the study drug and categorized according to the Medical Dictionary for Regulatory Activities.

Time frame: From enrollment to the end of treatment at 52 weeks.

Central Contacts

Qian Jia

CONTACT

028-88610620 clinicaltrial@keymedbio.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.